The ANKRD30B Knockout HEK293T Polyclonal Cells are a heterogeneous population of HEK293T cells in which the ANKRD30B gene has been disrupted via CRISPR/Cas9-mediated editing. As a polyclonal knockout pool, the product provides a loss-of-function model for studying ANKRD30B function without clonal isolation, thereby maintaining genetic diversity and minimizing clone-specific artifacts. Derived from human embryonic kidney cells, these cells express the SV40 large T antigen, which supports high-level episomal replication and protein expression.
HEK293T cells are an extensively characterized human embryonic kidney epithelial line that constitutively produces the SV40 large T antigen. This feature permits amplification of plasmids containing the SV40 origin, resulting in exceptionally high transient protein yields. Consequently, HEK293T cells have become a standard host for recombinant protein production, lentivirus packaging, and a broad array of genetic perturbation studies, offering a robust platform for functional genomics experiments.
ANKRD30B is a cancer-testis antigen with ankyrin repeat motifs that mediate protein interactions. It is predicted to act as a transcriptional coregulator, forming complexes with nuclear proteins and co-factors to regulate genes involved in proliferation and differentiation. Its expression is controlled by DNA methylation, histone modifications, and testis-specific transcription factors, and is normally testis-restricted but aberrantly activated in cancers. The protein interacts with ankyrin repeat binding partners that facilitate its recruitment to transcriptional complexes.
Disruption of ANKRD30B in HEK293T cells creates a valuable system for dissecting the gene??s contribution to transcriptional programs outside the germline or tumor environment. The polyclonal nature of the knockout captures a range of editing outcomes, enabling detection of robust phenotypes that are not biased by single-clone behavior. This model is particularly advantageous for studying ANKRD30B-dependent gene expression changes and their effects on cell growth, while the large T antigen facilitates complementation assays using episomally expressed constructs. By using a non-cancerous host, researchers can investigate ANKRD30B function without interference from oncogenic mutations.
These ANKRD30B Knockout HEK293T Polyclonal Cells support a range of experimental applications in cancer biology and transcriptional regulation. They are suitable for knockout validation by Western blot and RT-qPCR, and for examining ANKRD30B-interacting protein localization via immunofluorescence. RNA-seq can be employed to profile transcriptome-wide changes upon gene disruption, and cell-based assays can link ANKRD30B to proliferation or viability phenotypes. The cells thus serve as a tool for cancer-testis antigen characterization, discovery of transcriptional targets, and epigenetic studies. For further information or to request a quote, please contact Ascent Research.
